News & Updates

First-line cemiplimab monotherapy continues to provide durable overall (OS) and progression-free survival (PFS) benefits at 5 years compared with chemotherapy in advanced nonsmall cell lung cancer (NSCLC) patients with PD-L1 expression ≥50 percent, according to the results of the EMPOWER-Lung 1 study presented at WCLC 2024.

Hard physical activity and normotensive individuals and increasing systolic blood pressure (SBP) in those with hypertension each correlate with larger thoracic aortic size, suggests a study.

A mild developmental delay may occur following an infection of viral meningitis in preschool children, according to a study, noting that targeted follow-up must be considered.

Treatment with osimertinib following definitive chemoradiotherapy (CRT) demonstrates a manageable safety profile in patients with unresectable stage III EGFR-mutated nonsmall cell lung cancer (NSCLC), reports a study presented at WCLC 2024.

A novel prognostic model based on the viral loads of hepatitis B virus (HBV) demonstrates its utility in predicting and stratifying the risk of hepatocellular carcinoma (HCC) in noncirrhotic patients with chronic hepatitis B (CHB) who are not yet receiving antiviral therapy.